Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies
- PMID: 12394411
- DOI: 10.1097/00008877-200209000-00008
Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies
Abstract
The involvement of dopamine (DA) in drug reinforcement is well established, but much less in known about its contribution to addiction. We have used positron emission tomography to investigate in humans the role of DA in drug reinforcement, addiction and drug vulnerability. We have shown that during drug intoxication increases in striatal DA are associated with the drug's reinforcing effects only if the DA changes occur rapidly. These results corroborate the relevance of drug-induced DA increases and of pharmacokinetics in the rewarding effects of drugs in humans. During withdrawal, we have shown significant reductions in DA D(2) receptors and in DA release in drug abusers, which is likely to result in decreased sensitivity to non-drug-related reinforcing stimuli. The DA D(2) reductions were associated with decreased activity in the orbitofrontal cortex, which we postulate is one of the mechanisms underlying compulsive drug administration in the addict. In fact, during craving the orbitofrontal cortex becomes hyperactive in proportion to the desire for the drug. In non-drug-abusing subjects striatal DA D(2) receptors levels predicted the reinforcing responses to stimulant drugs, providing evidence that striatal DA D(2) receptors modulate reinforcing responses to stimulants in humans and may contribute to the predisposition for drug self-administration.
Comment on
-
There is more to dopamine than just pleasure. Commentary on Volkow et al. 'Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies'.Behav Pharmacol. 2002 Sep;13(5-6):367-70. doi: 10.1097/00008877-200209000-00009. Behav Pharmacol. 2002. PMID: 12394412 No abstract available.
-
From rats to humans and return: testing addiction hypotheses by combined PET imaging and self-reported measures of psychostimulant effects. Commentary on Volkow et al. 'Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies'.Behav Pharmacol. 2002 Sep;13(5-6):371-7. doi: 10.1097/00008877-200209000-00010. Behav Pharmacol. 2002. PMID: 12394413 No abstract available.
Similar articles
-
Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans.J Psychopharmacol. 1999 Dec;13(4):337-45. doi: 10.1177/026988119901300406. J Psychopharmacol. 1999. PMID: 10667609 Review.
-
Role of dopamine, the frontal cortex and memory circuits in drug addiction: insight from imaging studies.Neurobiol Learn Mem. 2002 Nov;78(3):610-24. doi: 10.1006/nlme.2002.4099. Neurobiol Learn Mem. 2002. PMID: 12559839
-
Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies.Eur Neuropsychopharmacol. 2002 Dec;12(6):557-66. doi: 10.1016/s0924-977x(02)00104-9. Eur Neuropsychopharmacol. 2002. PMID: 12468018 Review.
-
Dopamine in drug abuse and addiction: results of imaging studies and treatment implications.Arch Neurol. 2007 Nov;64(11):1575-9. doi: 10.1001/archneur.64.11.1575. Arch Neurol. 2007. PMID: 17998440 Review.
-
Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study.Synapse. 2002 Nov;46(2):79-82. doi: 10.1002/syn.10137. Synapse. 2002. PMID: 12211085
Cited by
-
High-affinity and selective dopamine D₃ receptor full agonists.Bioorg Med Chem Lett. 2012 Sep 1;22(17):5612-7. doi: 10.1016/j.bmcl.2012.07.003. Epub 2012 Jul 11. Bioorg Med Chem Lett. 2012. PMID: 22871578 Free PMC article.
-
Psychopathological symptoms of patients with heroin addiction entering opioid agonist or therapeutic community treatment.Ann Gen Psychiatry. 2014 Nov 18;13(1):35. doi: 10.1186/s12991-014-0035-x. eCollection 2014. Ann Gen Psychiatry. 2014. PMID: 25435897 Free PMC article.
-
The dopamine D2 receptor mediates approach-avoidance tendencies in smokers.Eur Arch Psychiatry Clin Neurosci. 2018 Apr;268(3):261-268. doi: 10.1007/s00406-017-0793-y. Epub 2017 Mar 31. Eur Arch Psychiatry Clin Neurosci. 2018. PMID: 28364268
-
Motivated explanation.Front Hum Neurosci. 2015 Oct 16;9:559. doi: 10.3389/fnhum.2015.00559. eCollection 2015. Front Hum Neurosci. 2015. PMID: 26528166 Free PMC article. Review.
-
The effect of SV 293, a D2 dopamine receptor-selective antagonist, on D2 receptor-mediated GIRK channel activation and adenylyl cyclase inhibition.Pharmacology. 2013;92(1-2):84-9. doi: 10.1159/000351971. Epub 2013 Aug 10. Pharmacology. 2013. PMID: 23942137 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical